Alivus Life Sciences Ltd (ALIVUS) Q3FY26 Concall Summary - Dec-2025 Qtr
Performance Overview
- The company reported its highest-ever quarterly EBITDA margin at 36.4%, an increase of 510 basis points year-over-year, driven by new product launches, a favorable product mix, and enhanced operational efficiencies.
- A significant turnaround was observed in the CDMO segment, which recorded exceptional performance with revenue growth of 100% quarter-over-quarter and 85.3% year-over-year, aligning with the company's H2 turnaround expectations.
- The company has upgraded its future margin guidance to a range of 30-32%, up from the previous 28-30%, reflecting strong confidence in the sustainability of operational improvements and contributions from new products.
- The company continues to maintain a debt-free balance sheet, supported by strong free cash flow generation of 221 crores in the first nine months of FY26 and a cash and cash equivalent balance of 733 crores.
- Strategic expansion initiatives at Solapur, Ankleshwar, and Dahej are progressing as planned, which are expected to provide a growth runway for the next two years, particularly for the regulated markets.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.